NIH's Role In Sustaining the U.S. Economy 2021 Update Now Available
here
UMR Urges House and Senate Leaders to Include NIH Funding in COVID Relief Package
read here
UMR releases new fact sheets on COVID-19 and biomedical research. Read
here
See how UMR members are aiding in the fight against the coronavirus
here
A new episode of the
Amazing Things Podcast is now available! Check it out
here.
A prominent virologist warns COVID-19 pill could unleash dangerous mutants. Others see little cause for alarm
The first oral antiviral for treating COVID-19, Merck & Co.’s molnupiravir, received approval from the U.K. Medicines and Healthcare products Regulatory Agency on 4 November. But the approval, for people at high risk of severe disease, comes as a prominent virologist has suggested using molnupiravir could do far more harm than good, potentially unleashing new, deadlier variants of SARS-CoV-2. Other virologists say the concern is worth tracking but is largely hypothetical, for now.
